Rheumatech AS is a company developing drugs that can be used to treat autoimmune disease and improve life quality of patients suffering from autoimmunity. This is achieved by targeting the generation of energy in white blood cells, a therapeutic strategy on the forefront of immunological science.
The increased understanding of the pathophysiology of autoimmune disease has revealed a number of bottlenecks/checkpoints that can be targeted in order to treat or dampen disease symptoms. These include key mediators of lymphocyte adhesion and migration, destructive cytokines involved in tissue damage, and the complex of molecules critical in the presentation of self-antigen and the activation of autoaggressive T cells. In many organ-specific autoimmune diseases, the identity of the molecules recognized and attacked by T cells and B cell derived antibodies is known. Despite this, efficient treatments of various autoimmunity conditions without severe side effects have not yet been developed.